These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
630 related articles for article (PubMed ID: 28241187)
1. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187 [TBL] [Abstract][Full Text] [Related]
2. Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis. Stolze T; Franke S; Haybaeck J; Moehler M; Grimminger PP; Lang H; Roth W; Gockel I; Kreuser N; Bläker H; Wittekind C; Lordick F; Vieth M; Veits L; Waidmann O; Lingohr P; Peitz U; Schildberg C; Kruschewski M; Vassos N; Goni E; Bruns CJ; Ridwelski K; Wolff S; Lippert H; Schumacher J; Malfertheiner P; Venerito M J Cancer Res Clin Oncol; 2023 Mar; 149(3):1007-1017. PubMed ID: 35211781 [TBL] [Abstract][Full Text] [Related]
3. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987 [TBL] [Abstract][Full Text] [Related]
4. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers. Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F; Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808 [TBL] [Abstract][Full Text] [Related]
7. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. Kim SM; An JY; Byeon SJ; Lee J; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S Eur J Surg Oncol; 2020 Jan; 46(1):189-194. PubMed ID: 31500870 [TBL] [Abstract][Full Text] [Related]
9. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022 [TBL] [Abstract][Full Text] [Related]
10. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812 [TBL] [Abstract][Full Text] [Related]
12. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649 [TBL] [Abstract][Full Text] [Related]
13. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Pietrantonio F; Miceli R; Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Morano F; Wotherspoon A; Valeri N; Kook MC; An JY; Grabsch HI; Fucà G; Noh SH; Sohn TS; Kim S; Di Bartolomeo M; Cunningham D; Lee J; Cheong JH; Smyth EC J Clin Oncol; 2019 Dec; 37(35):3392-3400. PubMed ID: 31513484 [TBL] [Abstract][Full Text] [Related]
14. Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases. Diniz G; Aktas S; Cubuk C; Ortac R; Vergin C; Olgun N Pediatr Hematol Oncol; 2013 May; 30(4):273-84. PubMed ID: 23570624 [TBL] [Abstract][Full Text] [Related]
15. [Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases]. Liu Y; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Zang FL; Qiu ZQ; Sun BC; Sun Y Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):369-375. PubMed ID: 33831997 [No Abstract] [Full Text] [Related]
16. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis. Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937 [TBL] [Abstract][Full Text] [Related]
18. Expression of Mismatch Repair Proteins in Early and Advanced Gastric Cancer in Poland. Karpińska-Kaczmarczyk K; Lewandowska M; Ławniczak M; Białek A; Urasińska E Med Sci Monit; 2016 Aug; 22():2886-92. PubMed ID: 27527654 [TBL] [Abstract][Full Text] [Related]
19. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Analysis of Mismatch Repair Gene Proteins in Early Gastric Cancer Based on Microsatellite Status. Sugimoto R; Endo M; Osakabe M; Toya Y; Yanagawa N; Matsumoto T; Sugai T Digestion; 2021; 102(5):691-700. PubMed ID: 33053554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]